Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Silo Pharma, Inc. (SILO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.7050-0.3550 (-11.60%)
At close: 04:00PM EST
2.7000 -0.00 (-0.18%)
After hours: 07:58PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close3.0600
Open2.9100
Bid2.7400 x 1800
Ask2.8000 x 3000
Day's Range2.6000 - 3.0200
52 Week Range0.1700 - 12.4500
Volume277,474
Avg. Volume535,852
Market Cap8.49M
Beta (5Y Monthly)-0.76
PE Ratio (TTM)0.83
EPS (TTM)3.2700
Earnings DateNov 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SILO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Silo Pharma, Inc.
    WPM: Lowering target price to $36.00WHEATON PRECIOUS METALS CORP has an Investment Rating of SELL; a target price of $36.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    Silo Pharma Announces Expansion of Intellectual Property Portfolio

    Silo Receives Issuance of U.S. Patent Covering SPC-15 Method for Treatment and Prevention of Stress-Induced Affective DisordersENGLEWOOD CLIFFS, NJ, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (USPTO) today issued U.S. Patent 11,491,120, titled “Pharmacological Prophylactics Against

  • GlobeNewswire

    Silo Pharma Announces Stock Repurchase Program

    ENGLEWOOD CLIFFS, NJ, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board of directors has authorized a share repurchase program to acquire up to $1,000,000 of the Company's common stock. The Company may purchase common stock in the open market, through privately negotiated transactions, or otherwise, in compliance w

  • GlobeNewswire

    Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation

    Parkinson's disease, bipolar disorder, and chronic pain targeted in study Study aims to support psilocybin as a potential therapeutic for inflammatory disorders ENGLEWOOD CLIFFS, NJ, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced a progress update on its sponsored research study with the University of California, San Francisco

Advertisement
Advertisement